StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)

Close on Nov 17, 2026Market cap $53.58MP/E –Yield –

Heron Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Heron Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$8.73M, down 345.5% year over year. For fiscal 2025 it was -$224.00K. The highest annual figure on record is -$224.00K in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$224.00K–
FY2024Dec 31, 2024-$9.04M–
FY2023Dec 31, 2023-$107.72M–
FY2022Dec 31, 2022-$171.77M–
FY2021Dec 31, 2021-$214.81M–
FY2020Dec 31, 2020-$225.32M–
FY2019Dec 31, 2019-$208.65M–
FY2018Dec 31, 2018-$182.42M–
FY2017Dec 31, 2017-$193.03M–
FY2016Dec 31, 2016-$169.82M–
FY2015Dec 31, 2015-$96.19M–
FY2014Dec 31, 2014-$73.98M–
FY2013Dec 31, 2013-$54.12M–
FY2012Dec 31, 2012-$23.63M–
FY2011Dec 31, 2011-$10.88M–
FY2010Dec 31, 2010-$9.71M–
FY2009Dec 31, 2009-$9.89M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.59M–
Q1 FY2026Mar 31, 2026-$4.24M-214.3%
Q4 FY2025Dec 31, 2025$575.00K-87.9%
Q3 FY2025Sep 30, 2025-$3.48M–
Q2 FY2025Jun 30, 2025-$1.03M–
Q1 FY2025Mar 31, 2025$3.71M–
Q4 FY2024Dec 31, 2024$4.75M–
Q3 FY2024Sep 30, 2024-$3.88M–
Q2 FY2024Jun 30, 2024-$5.80M–
Q1 FY2024Mar 31, 2024-$4.11M–
Q4 FY2023Dec 31, 2023-$9.51M–
Q3 FY2023Sep 30, 2023-$24.20M–
Q2 FY2023Jun 30, 2023-$41.66M–
Q1 FY2023Mar 31, 2023-$32.35M–
Q4 FY2022Dec 31, 2022-$19.56M–
Q3 FY2022Sep 30, 2022-$41.18M–
Q2 FY2022Jun 30, 2022-$48.83M–
Q1 FY2022Mar 31, 2022-$62.20M–
Q4 FY2021Dec 31, 2021-$52.74M–
Q3 FY2021Sep 30, 2021-$50.95M–
Q2 FY2021Jun 30, 2021-$59.74M–
Q1 FY2021Mar 31, 2021-$51.38M–
Q4 FY2020Dec 31, 2020-$60.58M–
Q3 FY2020Sep 30, 2020-$57.62M–
Q2 FY2020Jun 30, 2020-$55.00M–
Q1 FY2020Mar 31, 2020-$52.11M–
Q4 FY2019Dec 31, 2019-$58.80M–
Q3 FY2019Sep 30, 2019-$34.33M–
Q2 FY2019Jun 30, 2019-$51.29M–
Q1 FY2019Mar 31, 2019-$64.23M–
Q4 FY2018Dec 31, 2018-$50.89M–
Q3 FY2018Sep 30, 2018-$41.40M–
Q2 FY2018Jun 30, 2018-$38.52M–
Q1 FY2018Mar 31, 2018-$51.61M–
Q4 FY2017Dec 31, 2017-$61.51M–
Q3 FY2017Sep 30, 2017-$40.91M–
Q2 FY2017Jun 30, 2017-$41.64M–
Q1 FY2017Mar 31, 2017-$48.97M–
Q4 FY2016Dec 31, 2016-$46.50M–
Q3 FY2016Sep 30, 2016-$47.43M–

More Heron Therapeutics figures

See a number that looks wrong?